Comparisons of Curative and Side Effects of Chemoradiotherapy among Xinjiang Han, Uigur and Kazakh Esophageal Carcinoma Patients

Abstract

Objective: This study aimed to explore the differences in the curative and side effects of chemoradiotherapy on esophageal cancer (EC) among Xinjiang Han, Uigur and Kazakh patients. Methods: 170 patients with IIA stage-IV of esophageal squamous cell carcinoma were analyzed retrospectively. Based on different nationalities, they were divided into the Han, Uigur and Kazakh groups. The 1-, 2-and 3-year survival rates, incidence of the side effects (including hematological toxicities, radioactive esophagitis and percutaneous reactions) and application of antibiotics and harmonics were compared among the groups. There was no significant difference in the short-term curative effects among the Han, Uigur and Kazakh groups. The 1-2-and 3-year survival rates of the three groups were 84%, 40%, 26%; 78%, 27%, 18%; and 60%, 21%, 12% (x 2 =14.497, P<0.05). The incidence rate of hamatological toxicity ≥Grade 2 in the Kazakh group was significantly lower than that in the Han or Uigur group. Results: The incidence rates of radioactive esophagitis and percutaneous reactions Grade 2 in the Han group were significantly higher than those in the Uigur or Kazakh group. There was no significant difference in the types of applied antibiotics among the groups, but there were significant differences in the days of antibiotic application and proportion of patients receiving harmonics between the Hans and either of other groups. Conclusion: Chemoradiotherapy shows a better effect in the long-term survival rate among Han EC patients compared with Uigur or Kazakh EC patients. Uigur and Kazakh patients show a better tolerance to the side effects of chemoradiotherapy compared with Hans.

The relationship between the expression of VEGF, EGFR, and HER-2 mRNA in esophageal squamous cell carcinoma (ESCC) and clinicopathological features of different ethnic groups in Xinjiang

“…Based on the results of clinical efficacy and preliminary of experimental studies, and at the same time when we retrospectively analyzed 170 cases of ESCC patients from different ethnic groups and compared the efficacy and side effects of different ethnic groups during the clinical observation, we found that the short-term efficacy of esophageal cancer chemotherapy of Han, Uyghur, and Kazakh patients in Xinjiang were similar, but the long-term survivals were different: the Han patients were better than Uyghur and Kazakh. However, Uyghur and Kazakh patients’ side effects were relatively lighter, and they were better tolerated [ 8 ]. And we simultaneously applied ELISA and immunohistochemistry to detect the expression levels of VEGF, EGFR, ES, and HER-2 and the NF-kBp in serum and tissue of Han, Kazakh, and Uyghur ESCC patients, the results indicated that there were ethnic differences in serum tumor marker levels of Han, Uyghur, and Kazakh ESCC patients in Xinjiang [ 9 ].…”

Mutation differences in circulating tumor DNAs from non-small cell lung cancer patients between Uygur and Han populations

“…For example, a study of esophageal SCC pointed out that the tumors in Uygur patients showed more resistance to radiotherapy and chemotherapy than Han patients, and radiotherapy/chemotherapy resulted in longer survival of Han patients. [ 60 ] We can speculate that the in vivo condition of the Uygur patient confers a more suitable microenvironment for the occurrence, survival, and proliferation of SCCs. In addition, Uygur children in Xinjiang have higher obesity frequency than other Chinese ethnicities.…”

Retrospective Analyses of the Clinicopathological and Prognostic Features of Esophageal Squamous Cell Carcinoma in a Grade A Tertiary Hospital in Xinjiang, China

“…Although Zhang et al explored the differences in the curative and side effects of chemoradiotherapy on EC among Xinjiang Han, Uygur and Kazakh patients. But their sample size was not large enough, totaling 170 [11]. A piece of study has reported that 5-year OS of ESCC patients undergoing radiotherapy was about10% [8].…”